Genetic Glomerular Disease: The Current Challenges – But Future Advantages – for Drug Development for Monogenic Glomerulonephropathies (Alport, AMKD, TRPC6, & WT1)
Time: 12:00 pm
day: Pre-Conference Focus Day
Details:
- Using Alport syndrome as a case example, discuss how modern applied genetic testing relates to early diagnosis, clinical trial design, and treatment regimens
- Explore how patient advocacy can significantly enhance recruitment efforts for clinical trials through networks and platforms to reach patients directly
- Explore the unique insights these organizations provide regarding patient needs, concerns, and experiences, ensuring that trial designs incorporate patient perspectives and preferences to develop more patient-centered trials that address real-world concerns and improve retention rates
